What investment strategy does 4Bio Partners focus on?

4Bio Partners focuses on VC strategies in the private equity space.

How many portfolio companies does 4Bio Partners have?

4Bio Partners has 9 active portfolio companies and 1 fund tracked on GP Intel.

Where is 4Bio Partners headquartered?

4Bio Partners is headquartered in London, United Kingdom.

When was 4Bio Partners founded?

4Bio Partners was founded in 2018.

What sectors does 4Bio Partners invest in?

4Bio Partners invests across Healthcare.

Home/GPs/4Bio Partners

4Bio Partners

London, United Kingdom·Founded 2018·

Venture Capital

·4biocapital.com

4Bio Partners, which trades as 4BIO Capital, is a London-headquartered venture capital firm that invests exclusively in the advanced-therapies sector. It backs early-stage life-science companies developing cell and gene therapies,…Read full bio

AUM

–

Funds

Portfolio

Exits

SectorsHealthcare

Key facts

HQLondon, United Kingdom

Founded2018

Website4biocapital.com

Recent exits

No exits recorded yet.

Coverage notes

1 fund tracked, 9 portfolio companies (9 active · 0 realized). Verified weekly from public filings and deal announcements.

About 4Bio Partners

4BIO Partners (4BIO Capital) is one of the few venture capital firms investing exclusively in advanced therapies with approximately $300 million plus of assets under management as of December 2024 across Ventures II and Ventures III (Ventures III is 2023 vintage, with the Development Bank of Japan joining Ventures III in January 2024), headquartered in London. The firm was founded in 2015 as a specialist VC focused on advanced therapies and operates as 4BIO Partners LLP, FCA-regulated.

Investment thesis

4BIO Partners deploys capital through approximately three funds (4BIO Ventures I, II, III), targeting early-stage venture capital exclusively in advanced therapeutics addressing high unmet medical need. Sector focus spans cell and gene therapy, RNA-based therapeutics, targeted therapies, microbiome and broader advanced and emerging biotech modalities. Geographic deployment is global across the US, UK and Europe, London-based. The platform aims to take advanced therapy modalities (cell, gene, RNA) mainstream.

Recent activity

Recent realised exits include an antibody-drug conjugate and biotech acquisition (2024). Recent investments include oncology viral immunotherapy Series A (2025), gene therapy Series A (2024-2025) and radiopharmaceutical and targeted therapy Series A (2024-2025). The platform continues active deployment of Ventures III across the advanced therapeutics mandate. Detailed buyer names and multiple data available on Pro at €49/month.